Annexon (ANNX) Income from Continuing Operations (2019 - 2026)
Annexon's (ANNX) quarterly Income from Continuing Operations came in at 78070000.0 in Q1 2026, down 9.25% year-on-year from 86030380.59 in Q1 2025, and down 15.75% quarter-over-quarter from 67445000.0 in Q4 2025.
Annexon (ANNX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Annexon's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 78070000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 9.25% year-over-year to 78070000.0 in Q1 2026; TTM through Mar 2026 was 268045000.0, a 4.7% increase from a year earlier, with the FY2025 full-year figure at 441339000.0, down 31.76% from the prior year.
- Income from Continuing Operations eased to 78070000.0 in Q1 2026 per ANNX's latest filing, from 67445000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 39998000.0 in Q4 2022 and bottomed at 160890000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 71458000.0 (2025), against an average of 74213294.12.
- Across the five-year window, Income from Continuing Operations slumped 302.25% in 2023 and jumped 64.82% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 39998000.0 in 2022, then slumped by 302.25% to 160890000.0 in 2023, then soared by 64.82% to 56599000.0 in 2024, then retreated by 19.16% to 67445000.0 in 2025, then decreased by 15.75% to 78070000.0 in 2026.
- Per Business Quant, the three latest ANNX Income from Continuing Operations figures stand at 78070000.0 (Q1 2026), 67445000.0 (Q4 2025), and 62616000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Annexon | 1.02 Bn | 798.41 Mn | - | -78.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.07 Mn |
| Dec 31, 2025 | -67.45 Mn |
| Sep 30, 2025 | -62.62 Mn |
| Jun 30, 2025 | -59.91 Mn |
| Mar 31, 2025 | -71.46 Mn |
| Dec 31, 2024 | -56.60 Mn |
| Sep 30, 2024 | -78.85 Mn |
| Jun 30, 2024 | -74.36 Mn |
| Mar 31, 2024 | -70.62 Mn |
| Dec 31, 2023 | -160.89 Mn |
| Sep 30, 2023 | -78.77 Mn |
| Jun 30, 2023 | -82.85 Mn |
| Mar 31, 2023 | -54.96 Mn |
| Dec 31, 2022 | -40.00 Mn |
| Sep 30, 2022 | -84.77 Mn |
| Jun 30, 2022 | -53.21 Mn |
| Mar 31, 2022 | -86.25 Mn |
| Dec 31, 2021 | -47.75 Mn |
| Sep 30, 2021 | -35.60 Mn |
| Jun 30, 2021 | -31.29 Mn |